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Abstract
Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following
solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with EpsteineBarr virus
(EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here
we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20,
with signiﬁcant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment
option for patients unable to tolerate rituximab.
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1. Background

P

osttransplant lymphoproliferative disorders
(PTLDs) are diseases of lymphoid proliferation
in the setting of immunosuppression following solid
organ or allogeneic hematopoietic stem cell transplantation (HSCT). The majority of cases are related
to EpsteineBarr virus (EBV)-induced proliferation
of B-cells [1]. EBV is a double-stranded DNA virus
that infects B lymphocytes via the CD21 receptor
and leads to polyclonal B-cell proliferation via
expression of several viral oncogenes. In the setting
of acute infection, this prompts a T-cell-based
response to viral antigens, which rapidly clears the
virus. In some remaining cells the virus remains
latent as circular DNA [2]. Viral proliferation is
suppressed by cytotoxic T-cells in the immunocompetent host. However, in the setting of immune
suppression caused by myeloablative chemotherapy
prior to HSCT and graft-versus-host disease
(GVHD) prophylaxis or treatment, EBV can proliferate, leading to varying degrees of lymphoid

neoplasia. The World Health Organization classiﬁes
PTLD into several subtypes: nondestructive PTLD
(plasmacytic hyperplasia, ﬂorid follicular hyperplasia, and infectious mononucleosis-like subtypes),
polymorphic PTLD, monomorphic PTLD, and classical Hodgkin lymphoma-type PTLD [3].
The incidence of PTLD after allogeneic HSCT
varies widely between studies depending on patient
population, institutional practices, type of allogeneic
HSCT, and other factors. Some studies have placed
the overall incidence at approximately 1e3% at 10
years after transplant, with the highest risk in the 1st
year after transplant [4,5]. Risk factors for the
development of PTLD in patients undergoing HSCT
include T-cell depletion prior to transplant, recipient age 50 years or greater, chronic or acute GVHD,
degree of human leukocyte antigen (HLA)
mismatch between donor and recipient, and second
allogeneic HSCT [6]. Some of these risk factors are
associated with the need for more intensive immune
suppression following transplant, which likely contributes to the development of PTLD. Treatment of
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EBV-PTLD generally consists of reduction of immune suppression as tolerated and the use of the
anti-CD20 monoclonal antibody (MoAB) rituximab
in nondestructive, polymorphic, and monomorphic
PTLD [1,7]. In patients with relapsed or refractory
disease, and in those with certain high grade
monomorphic PTLD types such as Hodgkin’s lymphoma, Burkitt’s lymphoma, or primary central
nervous system lymphoma, treatment includes
standard-of-care chemo-immunotherapy regimens
according to the histologic subtype [7].
Recipients of haplo-cord HSCT, in which umbilical cord blood is supplemented by CD34 selected
donor cells, are among the highest risk for developing EBV-PTLD [8]. This may be mitigated by
pretransplant rituximab administration, with one
study showing an incidence of EBV-PTLD of 0%
among haplo-cord recipients who received pretransplant rituximab compared to 8% among those
who did not [8]. Pretransplant rituximab among
these high-risk patients has become standard protocol at New York Presbyterian Hospital/Weill
Cornell Medical Center.
Rituximab is a chimeric MoAB composed of murine variable regions linked to human IgG1 and
kappa constant regions [9]. The incidence of infusion reactions is approximately 77% with ﬁrst
administration of rituximab [10], and is often
manageable by slowing the infusion rate and with
supportive care including glucocorticoids and antihistamines. Ofatumumab, a fully human MoAB, has
been approved by the Food and Drug Administration (FDA) for the treatment of chronic lymphocytic
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leukemia. Here we present a case of a patient with
EBV-PTLD following allogeneic HSCT successfully
treated with ofatumumab.

2. Case presentation
A 56-year-old woman with secondary acute
myeloid leukemia (AML) transformed from an
antecedent myelodysplastic syndrome in complete
remission who underwent matched related donor
allogeneic HSCT in May 2019 was admitted in
September 2019 for management of EBV viremia.
The patient and her sibling donor tested positive for
EBV IgG, with undetectable viral load pre-transplant. Conditioning consisted of ﬂudarabine,
melphalan, and 400 cGy total body irradiation.
GVHD prophylaxis consisted of alemtuzumab and
tacrolimus. Antimicrobial prophylaxis included ﬂuconazole, valacyclovir, letermovir, and trimethoprimesulfamethoxazole. The patient’s immediate
posttransplant course was only notable for acute
kidney injury for which tacrolimus was brieﬂy
substituted for sirolimus, and the patient was discharged on post-HSCT Day 25.
Tacrolimus was discontinued in August 2019 according to protocol. Shortly thereafter, the patient
had stage 2, grade I biopsy proven acute GVHD of
the skin. She was started on methylprednisolone 1.6
mg/kg for 3 days, which was subsequently changed
to prednisone 0.5 mg/kg and tapered slowly over the
following month. On September 12, 2019, she was
taking prednisone 10 mg daily and her EBV viral
load was undetectable, however, when checked

Fig. 1. PETeCT illustrating FDG-avid lymphadenopathy above and below the diaphragm as well as FDG avidity of the spleen. (A) Baseline PETeCT
on hospital Day 2 showing FDG avid lymphadenopathy including a left axillary lymph node 2.2  1.1 cm, SUVmax 43.6, and FDG avidity
throughout the spleen. (B) Repeat PETeCT on hospital Day 39 showing improvement in FDG avid lymphadenopathy including left axillary lymph
node 1.7  0.9 cm with maximal SUV 9.5, and decreased FDG avidity of the spleen. Note. FDG ¼ ; PETeCT ¼ positron emission
tomographyecomputed tomography; SUV ¼ standardized uptake value.
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again on September 26, 2019. It was noted to be
65,965 copies/mL. The patient was admitted for
further management of EBV viremia and suspected
PTLD. Rituximab was started empirically on hospital
Day 1 given the high EBV viral load. However,
15 minutes into the infusion the patient developed
hypotension, fever, and rigors. The infusion was
held and blood pressure normalized after several
hours of intravenous ﬂuids and hydrocortisone.
Repeat EBV serum viral load on hospital Day 3 was
increased to >400,000 copies/mL. Positron emission
tomographyecomputed tomography (PETeCT)
showed multiple FDG avid lymph nodes above and

below the diaphragm including a left axillary lymph
node with a maximum standardized uptake value
(SUV) of 43.6 (Fig. 1). Excisional biopsy of the left
axillary lymph node was performed with pathology
showing effaced lymph node architecture with a
mixed population of cells including histiocytes,
plasma cells, small lymphocytes, and larger atypical
cells (Fig. 2). Flow cytometry showed a large population of CD19þ cells, a small subset of which
expressed CD20 (Fig. 3). Monoclonal IGH and IGK
rearrangements were seen on molecular studies.
Overall, these ﬁndings were consistent with EBVpositive polymorphic PTLD.

Fig. 2. Histologic sections of an enlarged lymph node demonstrate an atypical inﬂammatory inﬁltrate largely effacing lymphoid architecture, which
included variably sized lymphoid cells and numerous plasma cells (hematoxylin and eosin images taken with (A) 1.25; (B) 4; and (C) 20
objectives). Focal areas of necrosis were appreciated (not shown). Interspersed lymphocytes were predominantly CD3þ T-cells (D), with few CD20 (E)
or Pax5þ (not shown) B-cells. Numerous CD138þ plasma cells were interspersed (F) along with increased by scattered CD30þ cells (G). Many of the
plasma cells coexpressed CD56 (H). The process demonstrated an elevated Ki67 proliferative index, particularly in areas of the plasma cells (I). In situ
hybridization studies demonstrated the plasma cells were largely lambda-restricted [kappa (J) and lambda (K)] with numerous cells positive for the
EBV encoded small RNA EBER (L, 10; inset: 20 objective). Images DeK were taken with 10x objective. The cells were negative for the
EpsteineBarr virus (EBV) latent membrane protein 1 (not shown).
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On hospital Day 3, we treated the patient with
ofatumumab 300 mg with standard premedication.
The dose was titrated up to 700 mg on Day 5 and
1,000 mg on Day 6, without complication. On hospital Day 9, rituximab was attempted again but
discontinued 30 minutes into the infusion because
of recurrent hypotension, fever, and rigors similar to
her prior reaction. Ofatumumab was then restarted
at a dose of 2,000 mg on Days 10, 13, 17, and 21. The
patient tolerated these doses without difﬁculty. The
patient’s serum EBV viral load quickly decreased
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from >400,000 copies/mL on hospital Day 3 to 491
copies/mL over 14 days (Fig. 4).
The patient’s hospital course was complicated by
septic shock caused by Klebsiella pneumoniae
bacteremia on hospital Day 25 requiring a brief stay
at the medical intensive care unit. Ofatumumab was
held during this time which coincided with a rise in
serum EBV viral load, which again decreased when
ofatumumab was restarted twice weekly. The
improvement in EBV viral load corresponded with
the decrease in size and ﬂuorodeoxyglucose (FDG)

Fig. 3. Flow cytometry of the lymph node demonstrated an atypical lymphoplasmacytic population with slightly dim CD45 expression (A, blue)
compared to background lymphocytes (green), which showed variable CD19 (B, blue and I, purple) and CD38 (C, blue). They were negative for CD10
(D), CD5 (not shown), and largely negative for surface light chain expression (E). A small subset expressed CD20 (F). By staining for cytoplasmic
light chain (G), the atypical cells were lambda-restricted with partial expression of CD56 (H). The ﬁndings were consistent with a lymphoid neoplasm
with extensive plasmacytic differentiation. Molecular studies for IGH and IGK demonstrated clonal B cell gene rearrangement.
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Fig. 4. Trend of serum EpsteineBarr virus (EBV) viral load. Red lines indicate dates of attempted rituximab administration. Blue lines indicate dates of
ofatumumab administration.

avidity of lymphadenopathy on repeat PETeCT
performed on hospital Day 39 (Fig. 1). For
example, a left axillary lymph node on hospital Day
39 measured 1.7  0.9 cm with maximal SUV 9.5,
compared to 2.2  1.1 cm with maximal SUV 43.6 on
prior PETeCT. The patient is tentatively planned to
continue ofatumumab in the outpatient setting.

3. Discussion and conclusions
Although the majority of infusion reactions
related to MoABs are thought to be non-allergic and
potentially mediated by cytokine release from targeted cells, immunoglobulin E (IgE)-mediated type I
hypersensitivity reactions to foreign antigens can
also occur [10,11]. A major difference between the
two is that non-allergic infusion reactions would be
expected to diminish in severity with subsequent
dosing, whereas true allergic type I hypersensitivity
reactions would not [11]. Distinguishing between
the two can be difﬁcult. While non-allergic reactions
can be managed with slowed infusions and more
aggressive premedications, allergic responses are
more difﬁcult to manage and can require desensitization protocols when no acceptable alternative
drugs are available.
In the case presented, rituximab induced a prolonged potentially life-threatening grade 4 reaction
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI

CTCAE) criteria [12]. The intensity and almost immediate reaction were concerning for a true allergy.
When rituximab was reattempted several days later,
a similar reaction was seen. As a fully humanized
CD20-directed MoAB, we hypothesized that ofatumumab would be a reasonable alternative in the
treatment of EBV-PTLD without eliciting the type I
hypersensitivity reaction induced by rituximab.
Although ofatumumab is also associated with infusion reactions, the frequency and severity may be
less than those of rituximab, with some estimates of
the rate of infusion reactions being 61% for ofatumumab and 77% for rituximab [10].
Ofatumumab and rituximab are both type I
monoclonal antibodies targeting different epitopes
of CD20 and resulting in redistribution of CD20 into
lipid rafts [13]. Important differences in their
mechanisms of action have been seen. In studies of
B-cell non-Hodgkin lymphoma cell lines, ofatumumab was associated with greater C1q binding and
complement-dependent cytotoxicity (CDC) than
rituximab [13], as well as greater direct cell death
[14]. Antibody-dependent cellular cytotoxicity
appeared to be similar with both agents [14].
The use of ofatumumab in a rituximab-allergic
patient with chronic lymphocytic leukemia transformed to large B-cell lymphoma has been
described previously [15]. To our knowledge, this is
the ﬁrst reported use of ofatumumab for EBV-PTLD.
The efﬁcacy of ofatumumab in this case as
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measured by clinical, laboratory, and radiological
improvements suggests that it could be a viable
alternative for patients with EBV-PTLD unable to
tolerate rituximab.
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